Skip to content
Medical Health Aged Care

SoftSmile and ClearCorrect Announce Settlement

SoftSmile < 1 mins read

NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- SoftSmile, Inc., ClearCorrect Operating, LLC, and Institut Straumann AG announce that they have amicably settled all litigation and legal disputes between them. The companies had been engaged in several legal disputes in the United States and Pakistan.

About SoftSmile
SoftSmile is a New York-based technology company that helps orthodontists to deliver custom, high-quality, and affordable treatment to their patients. Established in 2020, SoftSmile designs and develops an advanced, AI-driven orthodontic software that applies innovative approaches in a user-friendly interface. This product gives orthodontists unparalleled control and precision of the treatment they deliver to their patients. SoftSmile was created by doctors, for doctors. Learn more at https://softsmile.com/.

MEDIA CONTACT:
[email protected]
[email protected]

Photos accompanying this announcement are available at: 
https://www.globenewswire.com/NewsRoom/AttachmentNg/c276b9bd-cacb-4e2e-ac2e-bc56a888f6dd

https://www.globenewswire.com/NewsRoom/AttachmentNg/1b28eb1a-5042-427c-9ef7-2e5b8eaf055e


Primary Logo

More from this category

  • General News, Medical Health Aged Care
  • 24/06/2025
  • 07:00
Monash University

Education status associated with reduced life expectancy and quality of life in Australia: new study

Australian males aged 25 years with a high level of education (completion of a bachelor’s degree or above) have 7.3 years greater life expectancy…

  • Contains:
  • Medical Health Aged Care
  • 24/06/2025
  • 06:00
Vertex

Vertex Announces Expanded Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People with Cystic Fibrosis

–With this reimbursement, approximately 45 people with cystic fibrosis in Australia will become eligible for a CFTR modulator for the first time – – The expanded listing includes an additional 271 mutations, many of them rare – Sydney, 24 June 2025 – Vertex Pharmaceuticals today announced that as of 1 July 2025, the funding of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) will be expanded on the Pharmaceutical Benefits Scheme (PBS) to include patients with cystic fibrosis aged 2years and older who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is considered responsive to elexacaftor/tezacaftor/ivacaftor potentiation…

  • Contains:
  • Medical Health Aged Care
  • 23/06/2025
  • 22:11
Novotech

Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges

SYDNEY–BUSINESS WIRE– As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.